Âé¶¹´«Ã½Ó³»­

Âé¶¹´«Ã½Ó³»­

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Muscle Thickness Measured by Ultrasound is Reduced in Neuromuscular Disorders and Correlates with Clinical and Electrophysiological findings
Neuromuscular and Clinical Neurophysiology (EMG)
P2 - Poster Session 2 (8:00 AM-9:00 AM)
1-003

To explore the potential of sonographic muscle thickness measurement to demonstrate the presence and the pattern of muscle atrophy in various neuromuscular disorders, and to determine the correlations of muscle thickness with clinical and electrophysiological measures.


Nerve imaging has limited sensitivity in various neuromuscular disorders, such as motor neuron diseases, axonal neuropathies, and muscle disorders.

We performed a prospective study from March to August 2018 of  patients attending the neuromuscular clinic. All patients underwent clinical evaluation and standardized muscle thickness measurement by ultrasound in 7 muscles. 


The study cohort consisted of 114 subjects , including patients with polyneuropathy, motor neuron disease and myopathy. The smallest distal muscle thickness was found in patients with polyneuropathy, while the smallest proximal muscle thickness was found in patients with myopathy. Muscle thickness was strongly correlated with muscle strength (r2 = 0.62), electrophysiological findings (r2: 0.44-0.55), and disability score (r2 = 0.53). 


Standardized muscle thickness measured by ultrasound shows diagnostic usefulness in a vast spectrum of neuromuscular disorders and correlates with clinical and electrophysiological findings.


Authors/Disclosures
Alon Abraham, MD (Tel Aviv Sourasky Medical Center)
PRESENTER
No disclosure on file
Vivian E. Drory, MD (Tel-Aviv Medical Center) Prof. Drory has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Teva. Prof. Drory has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Amylyx. Prof. Drory has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Takeda. Prof. Drory has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Argenx. Prof. Drory has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Medison Pharma. The institution of Prof. Drory has received research support from Neurosense Therapeutics. The institution of Prof. Drory has received research support from AB Science. The institution of Prof. Drory has received research support from Biogen. The institution of Prof. Drory has received research support from Neuralight.
No disclosure on file
Avi A. Algom, MD No disclosure on file
No disclosure on file
Vera Bril, MD (Toronto General Hospital) Dr. Bril has received personal compensation in the range of $500-$4,999 for serving as a Consultant for UCB. Dr. Bril has received personal compensation in the range of $500-$4,999 for serving as a Consultant for CSL. Dr. Bril has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alnylam. Dr. Bril has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Janssen. Dr. Bril has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Grifols. Dr. Bril has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Takeda. Dr. Bril has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Octapharma. Dr. Bril has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Pfizer. Dr. Bril has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Powell Mansfield. Dr. Bril has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Akcea. Dr. Bril has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Ionis. Dr. Bril has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Immunovant. Dr. Bril has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sanofi. Dr. Bril has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Dr. Bril has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Momenta (now J&J). Dr. Bril has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alexion. Dr. Bril has received personal compensation in the range of $500-$4,999 for serving as a Consultant for NovoNordisk. Dr. Bril has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Takeda. Dr. Bril has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Immunovant. Dr. Bril has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Dr. Bril has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Akcea. Dr. Bril has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi. Dr. Bril has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alnylam. Dr. Bril has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for CSL. Dr. Bril has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Argenx. The institution of Dr. Bril has received research support from UCB. The institution of Dr. Bril has received research support from Argenx. The institution of Dr. Bril has received research support from Momenta (now J&J). The institution of Dr. Bril has received research support from Immunovant. The institution of Dr. Bril has received research support from Alexion. The institution of Dr. Bril has received research support from Takeda. The institution of Dr. Bril has received research support from Grifols. The institution of Dr. Bril has received research support from CSL. The institution of Dr. Bril has received research support from Octapharma. The institution of Dr. Bril has received research support from Akcea. The institution of Dr. Bril has received research support from Ionis. The institution of Dr. Bril has received research support from Viela Bio (now Horizon). Dr. Bril has received intellectual property interests from a discovery or technology relating to health care.